系统性硬化症患者的癌症风险:韩国2004至2021年全国性队列研究
该研究利用韩国国民健康保险服务数据,纳入2004至2020年新诊断的6386例系统性硬化症患者,比较其与一般人群的癌症风险。结果显示系统性硬化症患者总体癌症(SIR 3.12;95%CI 2.92-3.33)、实体癌(SIR 3.07;95%CI 2.86-3.28)和血液系统癌症(SIR 5.70;95%CI 4.50-7.11)风险均升高,其中骨髓增生异常综合征风险最高(SIR 12.52;95%CI 7.00-20.65)。作者认为该强关联提示临床医生应对系统性硬化症患者进行仔细的癌症筛查。
要点
- 系统性硬化症患者总体癌症风险升高(SIR 3.12;95%CI 2.92-3.33)。
- 骨髓增生异常综合征风险最高(SIR 12.52;95%CI 7.00-20.65),其次为多发性骨髓瘤、眼癌、霍奇金淋巴瘤和喉癌。
- 癌症风险在20至39岁患者(SIR 5.27;95%CI 4.31-6.38)及诊断后第一年(SIR 4.44;95%CI 3.81-5.14)达到峰值。
核心结论
- 在韩国,系统性硬化症患者的癌症发生率高于一般人群。
- 系统性硬化症与癌症发生之间的强关联提示临床医生应对系统性硬化症患者进行仔细的癌症筛查。
研究设计与样本
- 研究基于韩国国民健康保险服务数据,纳入2004至2020年新诊断的系统性硬化症患者6386例。
- 计算标准化发病比(SIR)以比较系统性硬化症患者与一般人群的癌症风险。
- 按诊断时年龄、随访时长和免疫抑制剂使用进行亚组分析。
主要发现
- 多数患者为女性(80.2%),诊断时平均年龄±标准差为53.1±13.4岁。
- 系统性硬化症患者总体癌症风险升高(SIR 3.12;95%CI 2.92-3.33)。
- 实体癌风险升高(SIR 3.07;95%CI 2.86-3.28),血液系统癌症风险升高(SIR 5.70;95%CI 4.50-7.11)。
- 骨髓增生异常综合征风险最高(SIR 12.52;95%CI 7.00-20.65),其次为多发性骨髓瘤、眼癌、霍奇金淋巴瘤和喉癌。
- 癌症风险在20至39岁患者中达到峰值(SIR 5.27;95%CI 4.31-6.38),并在诊断后第一年达到峰值(SIR 4.44;95%CI 3.81-5.14)。
临床怎么用
- 作者认为,系统性硬化症与癌症发生之间的强关联提示临床医生应对系统性硬化症患者进行仔细的癌症筛查。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Systemic sclerosis (SSc) is a rare autoimmune disease characterized by tissue fibrosis, vasculopathy, and immune dysregulation. Our objectives were to quantify the overall and site-specific cancer risks in patients with SSc compared to the general population, examine temporal trends in cancer incidence following SSc diagnosis, and explore potential associations with immunosuppressive agent use. METHODS: Using data from the Korean National Health Insurance Service, we identified 6,386 patients newly diagnosed with SSc between 2004 and 2020. Standardized incidence ratios (SIRs) were calculated to compare the risk of cancer between patients with SSc and the general population. Subgroup analyses were performed based on age at diagnosis, follow-up duration, and immunosuppressive agent use. RESULTS: Most patients (80.2%) were women, with a mean ± SD age at diagnosis of 53.1 ± 13.4 years. Patients with SSc had higher risks of overall cancer (SIR 3.12; 95% confidence interval [CI] 2.92-3.33), solid cancer (SIR 3.07; 95% CI 2.86-3.28), and hematologic cancer (SIR 5.70; 95% CI 4.50-7.11) compared to the general population. Myelodysplastic syndrome (SIR 12.52; 95% CI 7.00-20.65) had the highest risk, followed by multiple myeloma, eye, Hodgkin lymphoma, and larynx cancers. Cancer risk peaked among patients aged 20 to 39 years (SIR 5.27; 95% CI 4.31-6.38) and during the first year after diagnosis (SIR 4.44; 95% CI 3.81-5.14). CONCLUSION: In this study, we revealed that the incidence of cancer is higher in patients with SSc in South Korea compared to the general population. The strong association between SSc and cancer occurrence prompts clinicians to conduct careful cancer screening for patients with SSc.
引用
- Na J, Choi SJ, Park S, et al. Cancer Risk in Patients With Systemic Sclerosis: A Nationwide Cohort Study in South Korea 2004 to 2021. Arthritis Care Res (Hoboken). 2025. PMID: 40598784. doi:10.1002/acr.25595
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。